Spots Global Cancer Trial Database for ici
Every month we try and update this database with for ici cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy | NCT04957511 | Gynecologic Can... Immunotherapy Gut Microbiome | 18 Years - | Viome | ||
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study | NCT04680598 | Hepatocellular ... | ICI Antiviral Proph... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma | NCT06377111 | Melanoma (Skin) | C-PAN Nivolumab Ipilimumab | 18 Years - | University Health Network, Toronto | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma | NCT06377111 | Melanoma (Skin) | C-PAN Nivolumab Ipilimumab | 18 Years - | University Health Network, Toronto | |
| Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer | NCT04712903 | Small Cell Lung... | Durvalumab Cisplatin Etoposide Carboplatin | 18 Years - | AstraZeneca | |
| Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer | NCT04712903 | Small Cell Lung... | Durvalumab Cisplatin Etoposide Carboplatin | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
